1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Turkey Pharmaceuticals and Healthcare Report Q4 2015

Turkey Pharmaceuticals and Healthcare Report Q4 2015

  • September 2015
  • -
  • Business Monitor International
  • -
  • 126 pages

Includes 3 FREE quarterly updates

BMI View: New medicine pricing rules introduced by the Turkish government will enable drugmakers toraise their prices following years of price suppression. We expect these changes to boost pharmaceuticalsales in value terms over the next 10 years and improve the commercial opportunities for pharmaceuticalmanufacturers. Despite this positive development, the pricing environment in Turkey will continue to bechallenging for drugmakers due to the ongoing enforcement of other government cost-containmentmeasures.

Headline Expenditure Projections

- Pharmaceuticals: TRY18.72bn (USD8.56bn) in 2014 to TRY20.81bn (USD7.85bn) in 2015; +11.1% inlocal currency and -8.3% US dollar terms.
- Healthcare: TRY95.78bn (USD43.78bn) in 2014 to TRY107.17bn (USD40.44bn) in 2015; +11.9% inlocal currency and -7.6% US dollar terms.

Table Of Contents

Turkey Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 13
Operational Risk 14
Industry Forecast 16
Pharmaceutical Market Forecast 16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Turkey 2011-2019) 18
Healthcare Market Forecast 19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 21
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 23
Patented Drug Market Forecast 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 25
Generic Drug Market Forecast 26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 30
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Turkey 2013-2019) 32
Table: Pharmaceutical Trade Data And Forecasts - Local Currency (Turkey 2013-2019) 33
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts 35
Economic Analysis 35
Table: Economic Activity (Turkey 2010-2019) 44
Industry Risk/Reward Indices 45
Central And Eastern Europe Risk/Reward Index - Q4 2015 45
Turkey Risk/Reward Index 51
Rewards 51
Risks 52
Market Overview 54
Industry Trends And Developments 55
Epidemiology 55
Healthcare Sector 57
Healthcare Insurance 57
Healthcare Infrastructure 58
Healthcare Financing 60
Table: Healthcare Resources (Turkey 2009-2014) 61
Table: Healthcare Personnel (Turkey 2009-2014) 61
Table: Healthcare Activity (Turkey 2009-2014) 62
Research and Development 62
Clinical Trials 64
Regulatory Development 65
Intellectual Property Regime 66
Market Access Issues 69
Pricing Regime 71
Table: Turkish Pharmaceutical Pricing Decrees 72
Reimbursement Regime 73
Table: Pharmacist Discount Related To Annual Sales Revenue (VAT Excluded) 75
Competitive Landscape 76
Pharmaceutical Sector 76
Research-Based Industry 77
Generic Drugmakers 78
Company Activity 79
Pharmaceutical Distribution 80
Pharmaceutical Retail 81
Company Profile 83
Abdi ?brahim 83
Bayer 87
EastPharma (Deva) 89
Eczaciba?i Healthcare 92
GlaxoSmithKline 95
Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals 98
Novartis 101
Pfizer 103
Roche 106
Sanofi 109
Sanovel Pharmaceuticals 112
Demographic Forecast 115
Table: Population Headline Indicators (Turkey 1990-2025) 116
Table: Key Population Ratios (Turkey 1990-2025) 116
Table: Urban/Rural Population and Life Expectancy (Turkey 1990-2025) 117
Table: Population By Age Group (Turkey 1990-2025) 117
Table: Population By Age Group % (Turkey 1990-2025) 118
Glossary 120
Methodology 122
Pharmaceutical Expenditure Forecast Model 122
Healthcare Expenditure Forecast Model 122
Notes On Methodology 123
Risk/Reward Index Methodology 124
Index Overview 125
Table: Pharmaceutical Risk/Reward Index Indicators 125
Indicator Weightings 126

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.